GlassScriptPhysician profile
Dana C Chan
NPI 1972820033
$9,004.60
in general payments reported to CMS, 2019-2025
21 companies · $677 in 2025
The $677 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,212 · 2020: $730 · 2021: $1,544 · 2022: $1,454 · 2023: $1,336 · 2024: $1,051 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,063.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,899.97 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $1,770.88 | 2022-2025 | Envista Mx60 Iol, Stellaris, Stellaris |
| Alcon Vision LLC | $1,269.20 | 2019-2025 | Clareon, Argos, Hydrus Microstent |
| Glaukos Corporation | $865.64 | 2019-2025 | Idose, Idosetr |
| Sight Sciences, INC. | $691.06 | 2019-2024 | Omni Surgical System |
| New World Medical,INC. | $589.05 | 2020-2023 | |
| Rxsight INC | $496.28 | 2021-2025 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $255.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $205.32 | 2019-2022 | |
| Allergan, INC. | $174.95 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $161.74 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $156.85 | 2024 | Veracity Surgical |
| Horizon Therapeutics Plc | $152.39 | 2022-2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $95.17 | 2019 | |
| Abbvie INC. | $64.97 | 2023-2024 | Lumigan, Vuity, Alphagan P |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $41.91 | 2023-2024 | Iyuzeh |
| Dompe US, INC. | $33.56 | 2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $23.16 | 2024 | Xdemvy |
| Shire North American Group INC | $19.47 | 2019 | |
| Oyster Point Pharma, INC. | $19.44 | 2025 | Ryzumvi, Tyrvaya |
| Mallinckrodt Hospital Products INC. | $18.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.